Table 1.

Demographic data for pancreas after islet (PAI) recipients prior to pancreas transplantation. Edmonton protocol consists of sirolimus, everolimus, and daclizumab (16).

Patient	Gender	Age at T1DM Diagnosis	Age at First Islet Txp	No. of Islet Infusions	Islet Transplant Immunosuppression	Duration of Insulin Independence (in mos.)	PRA Following Islet Txp	Maintenance Immunosuppression following Islet Failure
1	Female	11	24	1	Edmonton Protocol	0	91%	None
2	Female	23	32	2	Edmonton Protocol	2	11%	Tacrolimus, sirolimus
						0	11%
3	Female	6	40	3	Edmonton Protocol	0	0%	Tacrolimus, sirolimus, prednisone
						0	0%
						0	0%
4	Female	3	48	1	Belatacept-based Protocol	20.7	13%	Tacrolimus, mycophenolate
5	Male	2	38	1	No immunosuppression	0	10%	None
6	Female	20	40	2	Efalizumab-based Protocol	3.5	2%	Sirolimus, mycophenolate
						17.8	2%
7	Male	11	43	2	Belatacept-based Protocol	16	0%	Belatacept, sirolimus, mycophenolate
						11	2%